CU-06 is under clinical development by Thea Open Innovation SASU and currently in Phase I for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to GlobalData, Phase I drugs for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CU-06’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CU-06 is under development for the treatment of diabetic macular edema, wet macular degeneration, stroke, myocardial infarction, ulcerative colitis, and hereditary angioedema, colon cancer. It is administered through oral route. The drug candidate acts by targeting NF-κB inflammatory signaling pathway.
It was also under development for the treatment of diabetic retinopathy, acute respiratory distress syndrome, unstable angina, ulcerative colitis, and Crohn's disease.
Thea Open Innovation SASU overview
Thea Open Innovation SASU is a biotechnology company that aim is to identify, evaluate and support the most innovative developments in eye care, throughout licensing agreements and/or equity investments. The company is headquartered in Clermont Ferrand, A
For a complete picture of CU-06’s drug-specific PTSR and LoA scores, buy the report here.